IRINA KATKOVSKAYA OD
Prescription History 1699856021
Optometrist in Bronx, NY

NPI Status: Active since October 19, 2006

Contact Information

MMC - DEPT. OF OPHTHALMOLOGY
3400 BAINBRIDGE AVENUE
BRONX, NY
ZIP 10467
Phone: (718) 920-2020

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for IRINA KATKOVSKAYA OD, an active Optometrist specialist practicing in Bronx, NY. Our medical registry currently tracks 7 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 862 documented patient claims. Among these therapy options, the most frequently utilized medication is Latanoprost, which accounts for 452 claims alone.


Brimonidine Tartrate

Generic Formulation: Brimonidine TartrateSpecialty: Optometry
Provider Metrics Summary
Total Claims 138
30-Day Fills 207.5
Days Supply 6,032
NY State Average Benchmarks
Peer Average Claims61.0
Peer Average 30-Day Fills105.3
Peer Average Days Supply3,022
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 126.2% higher than the standard regional baseline profile for NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $5,274.28 across this reporting matrix range.

Provider Avg Cost Per Claim

$38.22

State Avg Cost Per Claim

$70.70

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A quinoxaline derivative and ADRENERGIC ALHPA-2 RECEPTOR AGONIST that is used to manage INTRAOCULAR PRESSURE associated with OPEN-ANGLE GLAUCOMA and OCULAR HYPERTENSION.

Therapeutic Applications

This medication is used to treat open-angle glaucoma or high fluid pressure in the eye. Lowering high fluid pressure in the eye reduces the risk of vision loss, nerve damage, or blindness. This medication lowers pressure by allowing better fluid drainage from within the eye and also by reducing the amount of fluid formed in the eye. It is known as an alpha agonist. This drug is not recommended for use in children less than 2 years of age due to an increased risk of serious side effects such as very slowed breathing. Ask the doctor or pharmacist for details.

Dorzolamide Hcl

Generic Formulation: Dorzolamide HclSpecialty: Optometry
Provider Metrics Summary
Total Claims 69
30-Day Fills 89.7
Days Supply 2,691
NY State Average Benchmarks
Peer Average Claims48.0
Peer Average 30-Day Fills89.7
Peer Average Days Supply2,675
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 43.8% more claims than the standard regional baseline profile for NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,297.94 across this reporting matrix range.

Provider Avg Cost Per Claim

$18.81

State Avg Cost Per Claim

$30.75

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Dorzolamide is used to treat high pressure inside the eye due to glaucoma (open angle-type) or other eye diseases (such as ocular hypertension). Lowering high pressure inside the eye helps to prevent blindness. This medication works by decreasing the amount of fluid within the eye. It belongs to a class of drugs known as carbonic anhydrase inhibitors.

Dorzolamide-Timolol

Generic Formulation: Dorzolamide Hcl/Timolol MaleatSpecialty: Optometry
Provider Metrics Summary
Total Claims 121
30-Day Fills 178.8
Days Supply 5,360
NY State Average Benchmarks
Peer Average Claims90.0
Peer Average 30-Day Fills175.1
Peer Average Days Supply5,241
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 34.4% more claims than the standard regional baseline profile for NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $2,644.81 across this reporting matrix range.

Provider Avg Cost Per Claim

$21.86

State Avg Cost Per Claim

$32.93

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product contains two drugs used to treat high pressure inside the eye due to glaucoma (open angle-type) or other eye diseases (such as ocular hypertension). Lowering high pressure inside the eye helps to prevent blindness. This medication works by decreasing the amount of fluid within the eye. Timolol belongs to a class of drugs known as beta-blockers, and dorzolamide belongs to a class of drugs known as carbonic anhydrase inhibitors.

Latanoprost

Generic Formulation: LatanoprostSpecialty: Optometry
Provider Metrics Summary
Total Claims 452
30-Day Fills 630.5
Days Supply 17,512
NY State Average Benchmarks
Peer Average Claims149.0
Peer Average 30-Day Fills254.5
Peer Average Days Supply7,268
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 203.4% higher than the standard regional baseline profile for NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $7,072.98 across this reporting matrix range.

Provider Avg Cost Per Claim

$15.65

State Avg Cost Per Claim

$20.93

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A prostaglandin F analog used to treat OCULAR HYPERTENSION in patients with GLAUCOMA.

Therapeutic Applications

Latanoprost is used to treat high pressure inside the eye due to glaucoma (open angle type) or other eye diseases (such as ocular hypertension). It is similar to a natural chemical in the body (prostaglandin) and works by regulating the flow of fluid within the eye which results in lower pressure. Lowering high pressure inside the eye helps to prevent blindness.

Pilocarpine Hcl

Generic Formulation: Pilocarpine HclSpecialty: Optometry
Provider Metrics Summary
Total Claims 17
30-Day Fills 29.9
Days Supply 897
NY State Average Benchmarks
Peer Average Claims32.0
Peer Average 30-Day Fills64.1
Peer Average Days Supply1,906
Conservative Utilization

This provider writes prescriptions for this formulation 46.9% less frequently than the standard regional baseline metric for practitioners inside NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,069.70 across this reporting matrix range.

Provider Avg Cost Per Claim

$62.92

State Avg Cost Per Claim

$82.18

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A slowly hydrolyzed muscarinic agonist with no nicotinic effects. Pilocarpine is used as a miotic and in the treatment of glaucoma.

Therapeutic Applications

This medication is used to treat symptoms of dry mouth due to a certain immune disease (Sjogren's syndrome) or from saliva gland damage due to radiation treatments of the head/neck for cancer. Pilocarpine belongs to a class of drugs known as cholinergic agonists. It works by stimulating certain nerves to increase the amount of saliva you produce, making it easier and more comfortable to speak and swallow.

Prednisolone Acetate

Generic Formulation: Prednisolone AcetateSpecialty: Optometry
Provider Metrics Summary
Total Claims 30
30-Day Fills 42.6
Days Supply 1,118
NY State Average Benchmarks
Peer Average Claims135.0
Peer Average 30-Day Fills176.5
Peer Average Days Supply4,637
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 77.8% less volume than the regional standard for practitioners inside NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,011.62 across this reporting matrix range.

Provider Avg Cost Per Claim

$33.72

State Avg Cost Per Claim

$52.63

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain eye conditions due to inflammation or injury. Prednisolone works by relieving symptoms such as swelling, redness, and itching. It belongs to a class of drugs known as corticosteroids.

Timolol Maleate

Generic Formulation: Timolol MaleateSpecialty: Optometry
Provider Metrics Summary
Total Claims 35
30-Day Fills 66.1
Days Supply 1,972
NY State Average Benchmarks
Peer Average Claims70.0
Peer Average 30-Day Fills139.2
Peer Average Days Supply4,099
Conservative Utilization

This provider writes prescriptions for this formulation 50.0% less frequently than the standard regional baseline metric for practitioners inside NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $453.32 across this reporting matrix range.

Provider Avg Cost Per Claim

$12.95

State Avg Cost Per Claim

$38.85

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A beta-adrenergic antagonist that is similar in action to PROPRANOLOL; the levo-isomer is more active. Timolol has been proposed as an anti-hypertensive, anti-arrhythmic, anti-angina, and anti-glaucoma agent. It is also used in the treatment of MIGRAINE DISORDERS and tremor.

Therapeutic Applications

This medication is used to treat high pressure inside the eye due to glaucoma (open angle-type) or other eye diseases (such as ocular hypertension). Lowering high pressure inside the eye helps to prevent blindness. This medication works by decreasing the amount of fluid within the eye. Timolol belongs to a class of drugs known as beta-blockers.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like IRINA KATKOVSKAYA OD provides transparency into local medical care patterns within Bronx, NY.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Optometrist** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.